Literature DB >> 16330499

Disulphide-reduced superoxide dismutase-1 in CNS of transgenic amyotrophic lateral sclerosis models.

P Andreas Jonsson1, Karin S Graffmo, Peter M Andersen, Thomas Brännström, Mikael Lindberg, Mikael Oliveberg, Stefan L Marklund.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease afflicting the voluntary motor system. More than 100 different mutations in the ubiquitously expressed enzyme superoxide dismutase-1 (SOD1) have been associated with the disease. To search for the nature of the cytotoxicity of mutant SOD1s, amounts, enzymic activities and structural properties of the protein as well as the CNS histopathology were examined in multiple transgenic murine models. In order to generate the ALS phenotype within the short lifespan of the mouse, more than 20-fold increased rates of synthesis of mutant SOD1s appear to be required. The organs of transgenic mice expressing human wild-type SOD1 or either of the G93A and D90A mutant proteins showed high steady-state protein levels. The major proportion of these SOD1s in the CNS were inactive due to insufficient Cu charging and all contained subfractions with a reduced C57-C146 intrasubunit disulphide bond. Both G85R and the truncated G127insTGGG mutant showed low steady-state protein levels, lacked enzyme activity and had no C57-C146 disulphide bond. These mutants were also enriched in the CNS relative to other organs, suggesting inefficient recognition and degradation of misfolded disulphide-reduced SOD1 in susceptible tissues. In end-stage disease, despite 35-fold differences in levels of mutant SOD1s, similar amounts of detergent-resistant aggregates accumulated in the spinal cord. Small granular as well as larger more diffuse human SOD1 (hSOD1)-inclusions developed in all strains, the latter more pronounced in those with high hSOD1 levels. Widespread vacuolizations were seen in the strains with high levels of hSOD1 but not those with low, suggesting these alterations to be artefacts related to high hSOD1 levels and not to the ALS-causing cytotoxicity. The findings suggest that the motoneuron degeneration could be due to long-term exposure to misfolded aggregation-prone disulphide-reduced SOD1, which constitutes minute subfractions of the stable mutants and larger proportions of the unstable mutants.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16330499     DOI: 10.1093/brain/awh704

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  117 in total

1.  Disulfide cross-linked protein represents a significant fraction of ALS-associated Cu, Zn-superoxide dismutase aggregates in spinal cords of model mice.

Authors:  Yoshiaki Furukawa; Ronggen Fu; Han-Xiang Deng; Teepu Siddique; Thomas V O'Halloran
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-24       Impact factor: 11.205

2.  Conversion to the amyotrophic lateral sclerosis phenotype is associated with intermolecular linked insoluble aggregates of SOD1 in mitochondria.

Authors:  Han-Xiang Deng; Yong Shi; Yoshiaki Furukawa; Hong Zhai; Ronggen Fu; Erdong Liu; George H Gorrie; Mohammad S Khan; Wu-Yen Hung; Eileen H Bigio; Thomas Lukas; Mauro C Dal Canto; Thomas V O'Halloran; Teepu Siddique
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-24       Impact factor: 11.205

3.  Structures of mouse SOD1 and human/mouse SOD1 chimeras.

Authors:  Sai V Seetharaman; Alexander B Taylor; Stephen Holloway; P John Hart
Journal:  Arch Biochem Biophys       Date:  2010-08-19       Impact factor: 4.013

4.  Structural basis of Cu, Zn-superoxide dismutase amyloid fibril formation involves interaction of multiple peptide core regions.

Authors:  Masataka Ida; Mizuho Ando; Masayuki Adachi; Asumi Tanaka; Kodai Machida; Kunihiro Hongo; Tomohiro Mizobata; Miho Yoshida Yamakawa; Yasuhiro Watanabe; Kenji Nakashima; Yasushi Kawata
Journal:  J Biochem       Date:  2015-08-29       Impact factor: 3.387

5.  Transcriptional profiling in the lumbar spinal cord of a mouse model of amyotrophic lateral sclerosis: a role for wild-type superoxide dismutase 1 in sporadic disease?

Authors:  Antonello D'Arrigo; Davide Colavito; Emiliano Peña-Altamira; Michele Fabris; Mauro Dam; Antonio Contestabile; Alberta Leon
Journal:  J Mol Neurosci       Date:  2010-02-23       Impact factor: 3.444

6.  Proteins that bind to misfolded mutant superoxide dismutase-1 in spinal cords from transgenic amyotrophic lateral sclerosis (ALS) model mice.

Authors:  Per Zetterström; Karin S Graffmo; Peter M Andersen; Thomas Brännström; Stefan L Marklund
Journal:  J Biol Chem       Date:  2011-04-14       Impact factor: 5.157

7.  Endoplasmic reticulum stress leads to accumulation of wild-type SOD1 aggregates associated with sporadic amyotrophic lateral sclerosis.

Authors:  Danilo B Medinas; Pablo Rozas; Francisca Martínez Traub; Ute Woehlbier; Robert H Brown; Daryl A Bosco; Claudio Hetz
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-23       Impact factor: 11.205

8.  Progressive aggregation despite chaperone associations of a mutant SOD1-YFP in transgenic mice that develop ALS.

Authors:  Jiou Wang; George W Farr; Caroline J Zeiss; Diego J Rodriguez-Gil; Jean H Wilson; Krystyna Furtak; D Thomas Rutkowski; Randal J Kaufman; Cristian I Ruse; John R Yates; Steve Perrin; Mel B Feany; Arthur L Horwich
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-26       Impact factor: 11.205

9.  Soluble misfolded subfractions of mutant superoxide dismutase-1s are enriched in spinal cords throughout life in murine ALS models.

Authors:  Per Zetterström; Heather G Stewart; Daniel Bergemalm; P Andreas Jonsson; Karin S Graffmo; Peter M Andersen; Thomas Brännström; Mikael Oliveberg; Stefan L Marklund
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-21       Impact factor: 11.205

10.  Using theoretical protein isotopic distributions to parse small-mass-difference post-translational modifications via mass spectrometry.

Authors:  Timothy W Rhoads; Jared R Williams; Nathan I Lopez; Jeffrey T Morré; C Samuel Bradford; Joseph S Beckman
Journal:  J Am Soc Mass Spectrom       Date:  2012-12-18       Impact factor: 3.109

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.